ObesityNCT06473831
MagDI Australia Study
A study testing Magnet System, DI Biofragmentable in people with Obesity and Type 2 Diabetes, run by GT Metabolic Solutions, Inc. at 4 sites in Australia.
Trial summary
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e.g., one example of a small bowel… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obesity, Type 2 Diabetes
- What is being tested?
- Magnet System, DI Biofragmentable
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 4 sitesAustralia
- Study dates
- 13 Aug 2024to 25 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Between 18-65 years of age, at the time of informed consent.
- Body Mass Index (BMI) between 30-50 kg/m2
- Meets one of the following criteria:
- Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) following previous sleeve gastrectomy (≥ 12 months); OR
- Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) without previous sleeve gastrectomy and without plan to perform a concurrent sleeve gastrectomy.
- Weight regain following previous sleeve gastrectomy (≥ 12 months).
Show all 9Show fewer
- Participant agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study.
- Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent.
- Participant is indicated for, and has agreed to, a bariatric procedure involving a duodenal ileal anastomosis. The participant has also undergone the site standard of care evaluation for this type of procedure, which is expected to involve clinical assessments over a period of time by a multidisciplinary team and may include, but is not limited to, the following: screening for surgical safety, interviews to determine if the participant understands the procedure and post-operative demands, and whether the participant has the necessary social supports in place to help manage outcomes.
Who cannot join
- Type 1 diabetes.
- Use of injectable insulin.
- Uncontrolled Type 2 Diabetes Mellitus (T2DM).
- Investigator plans to perform a sleeve gastrectomy with the duodeno-ileal anastomosis procedure.
- Uncontrolled hypertension, dyslipidemia or sleep apnea.
- Prior intestinal, colonic or duodenal surgery (other than bariatric).
Show all 31Show fewer
- Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the procedure, including scarring and abnormal anatomy.
- Refractory gastro-esophageal reflux disease (GERD).
- Barrett's disease.
- Helicobacter pylori positive and/or active ulcer disease.
- Large hiatal hernia.
- Inflammatory bowel or colonic diverticulitis disease.
- Any anomaly precluding orogastric access by gastroscope and catheters, and manipulation techniques.
- Any anomaly preventing / contraindicating endoscopic or laparoscopic access and procedures.
- Implantable pacemaker or defibrillator.
- Psychiatric disorder, except well-controlled depression with medication for > 6 months.
- History of substance abuse.
- Pregnant, lactating, or planning pregnancy during the clinical investigation. Note: Female participants of childbearing age must agree to use safe contraception (e.g., intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release).
- Any comorbidity or current status of participant's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the participant medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets.
- Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment site.
- Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months post-procedure.
- Any surgical or interventional procedure (including planned and/or scheduled) within the period of 30 days prior to and 30 days following the study procedure.
- Any stroke/TIA ≤ 6 months prior to consent.
- Requires chronic anticoagulation therapy (except aspirin).
- Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure.
- Recent tobacco or nicotine product cessation ≤ 3 months prior to informed consent.
- Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.
- Participants with comorbidities that are likely to result in a life expectancy of ≤ 12 months.
- Currently participating in an investigational drug or another device study that has not reached its primary endpoint: Note: Studies requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- A positive COVID-19 test prior to the study procedure in accordance with local COVID-19 protocol.
- Presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
Trial locations and contacts
4 sites in 1 country.
Australia4 sites
Calvary Health Care Adelaide Limited
Adelaide
St. John of God Health Care, Inc.
Murdoch, Western Australia, 6150
Dr. Mark Magdy (affiliated with St. George Private Hospital)
Sydney, New South Wales, 2217
Upper GI Surgery
Sydney
About this study
Official title: Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System) in Australia to Achieve Duodeno-Ileostomy Diversion in Adults With Obesity and With or Without Type 2 Diabetes Mellitus (MagDI Australia Study)
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e.g., one example of a small bowel clinical procedure requiring a side-to-side anastomosis).
Read the detailed description
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e.g., one example of a small bowel clinical procedure requiring a side-to-side anastomosis).
The partial diversion of intestinal contents from the duodenum to the ileum via side-to-side duodeno-ileostomy is intended to facilitate weight management / loss in obese adults and improve metabolic outcomes in obese adults with and without type 2 diabetes mellitus (T2DM). Side-to-side anastomoses are currently created by sutures, staples, and anastomotic compression devices. The most common side-to-side anastomosis technique used today is stapling, requiring cutting of the intestines and staples remain behind in the body. Linear staplers are available in different sizes (e.g., 30mm, 45mm, 50mm, 60mm). A predicate for this side-to-side duodeno-ileostomy diversion procedure is the single-anastomosis duodeno-ileostomy (SADI) procedure.
- Conditions
- Obesity, Type 2 Diabetes
- Being tested
- Magnet System, DI Biofragmentable
- Medical subject headings
- Obesity, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnet System, DI BiofragmentableDevice
Anastomoses achieved by magnetic compression.
| Study group | Role | What they receive |
|---|---|---|
| Magnet System, DI Biofragmentable | Experimental | GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System) Receives: Device: Magnet System, DI Biofragmentable |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility and performance of the side-to-side anastomosis for duodeno-ileal diversion using the MagDI System.
The duodeno-ileal diversion will be considered feasible if it results in successful:
- Placement of the Magnet System (≥ 90% alignment of magnets); and
- Creation of a patent anastomosis confirmed radiologically, and
- Passage of magnets without any surgical re-interventions.
The primary endpoint will be met if the feasibility/performance is confirmed in ≥ 80% of enrolled and treated subjects.
Measured: From date of study index procedure through 90 days
Safety of the MagDI System
Freedom from serious adverse events related to the study device or study device procedure requiring additional emergency surgery or re-intervention, including:
- All-cause mortality
- Intestinal perforation and/or peritonitis
- Intestinal obstruction
- Life-threatening bleeding
- Incidence of device malfunctions
Measured: Procedure, Day 90, Day 180, Day 360
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2024
- Study start13 Aug 2024
- Primary completion4 Sep 2025
- Study completion25 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is an open-label multicenter study enrolling up to 30 participants at up to 3 sites in Australia.
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- GT Metabolic Solutions, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06473831
- Sponsor's protocol ID
- GTM-009
- Status last verified
- Sep 2026
- First submitted
- 19 Jun 2024
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System) in Australia to Achieve Duodeno-Ileostomy Diversion in Adults With Obesity and With or Without Type 2 Diabetes Mellitus (MagDI Australia Study)
- ClinicalTrials.gov ID
- NCT06473831
- Acronym / sponsor ID
- GTM-009
- Conditions
- Obesity, Type 2 Diabetes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- GT Metabolic Solutions, Inc.Industry (pharma, biotech, devices)
- Study start
- 13 Aug 2024 (actual)
- Primary completion
- 4 Sep 2025 (actual)
- Study completion
- 25 Jun 2026 (actual)
- First posted
- 25 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e.g., one example of a small bowel clinical procedure requiring a side-to-side anastomosis).
Detailed description
The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e.g., one example of a small bowel clinical procedure requiring a side-to-side anastomosis).
The partial diversion of intestinal contents from the duodenum to the ileum via side-to-side duodeno-ileostomy is intended to facilitate weight management / loss in obese adults and improve metabolic outcomes in obese adults with and without type 2 diabetes mellitus (T2DM). Side-to-side anastomoses are currently created by sutures, staples, and anastomotic compression devices. The most common side-to-side anastomosis technique used today is stapling, requiring cutting of the intestines and staples remain behind in the body. Linear staplers are available in different sizes (e.g., 30mm, 45mm, 50mm, 60mm). A predicate for this side-to-side duodeno-ileostomy diversion procedure is the single-anastomosis duodeno-ileostomy (SADI) procedure.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is an open-label multicenter study enrolling up to 30 participants at up to 3 sites in Australia.
| Arm | Type | Receives |
|---|---|---|
| Magnet System, DI Biofragmentable | Experimental | Device: Magnet System, DI BiofragmentableGT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System) |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Between 18-65 years of age, at the time of informed consent.
- Body Mass Index (BMI) between 30-50 kg/m2
- Meets one of the following criteria:
- Participant agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study.
- Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent.
Key exclusion criteria (31 listed)
- Type 1 diabetes.
- Use of injectable insulin.
- Uncontrolled Type 2 Diabetes Mellitus (T2DM).
- Investigator plans to perform a sleeve gastrectomy with the duodeno-ileal anastomosis procedure.
- Uncontrolled hypertension, dyslipidemia or sleep apnea.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnet System, DI BiofragmentableAnastomoses achieved by magnetic compression. | Device | Magnet System, DI Biofragmentable |
Primary outcome
Feasibility and performance of the side-to-side anastomosis for duodeno-ileal diversion using the MagDI System.
Time frame: From date of study index procedure through 90 days
The duodeno-ileal diversion will be considered feasible if it results in successful: * Placement of the Magnet System (≥ 90% alignment of magnets); and * Creation of a patent anastomosis confirmed radiologically, and * Passage of magnets without any surgical re-interventions. The primary endpoint will be met if the feasibility/performance is confirmed in ≥ 80% of enrolled and treated subjects.
Safety of the MagDI System
Time frame: Procedure, Day 90, Day 180, Day 360
Freedom from serious adverse events related to the study device or study device procedure requiring additional emergency surgery or re-intervention, including: * All-cause mortality * Intestinal perforation and/or peritonitis * Intestinal obstruction * Life-threatening bleeding * Incidence of device malfunctions
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity
Active, not recruiting
Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial
Bariatric Surgery Candidate, Obesity
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Not yet recruitingPhase 1
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Healthy Participants
Not yet recruiting
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Obese Adults
Not yet recruiting
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnet System, DI Biofragmentable in people with Obesity and Type 2 Diabetes, run by GT Metabolic Solutions, Inc. at 4 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility and performance of the side-to-side anastomosis for duodeno-ileal diversion using the MagDI System. (time frame: From date of study index procedure through 90 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.